At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 5 enrolled
Drug / intervention
Ascorbic Acid + Sorafenib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Study of Intravenous Ascorbic Acid in Treatment of Metastatic Hepatocellular Carcinoma
In Brief
A Phase 2 clinical trial evaluating Ascorbic Acid + Sorafenib and Sorafenib for Metastatic Hepatocellular Carcinoma and Advanced Liver Cancer. Completed, enrolled 5 participants across 1 site.
Detailed Summary
This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment with sorafenib versus treatment with sorafenib alone in subjects with metastatic hepatocellular carcinoma. The phase I aspect will assess the safety and efficacy of the concurrent treatments and the phase II aspect will utilize CT (computer-tomography) scans to assess overall tumor response rate and evaluate disease progression
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2012
First PostedDec 2012
Primary CompletionJan 2016
TodayJul 2026
First PostedDec 21, 2012
Enrollment StartSep 1, 2012
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 13.5 years ago
Interventions
Ascorbic Acid + Sorafenibdrug
Sorafenibdrug